Systemic N‐Acylethanolamines and Other Lipid Mediators Are Associated With NSAID ‐Exacerbated Respiratory Disease
Clinical & Experimental Allergy · 2026-01 · 56 (1) · 95-98
DOI: 10.1111/cea.70145 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 18.09.2025. Verfasst von Viljami E Salmi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jalmari ja Rauha Ahokkaan Säätiö, Suomen Allergologi- ja immunologiyhdistys, Suomen Rinologiyhdistys - Consociatio Rhinologica Fennica.
Abstract (Originalsprache)
Nonsteroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease (N-ERD) is a common chronic airway inflammatory disease characterised by asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and hypersensitivity to NSAIDs, including acetylsalicylic acid (ASA, aspirin), posing a significant burden on respiratory health [1]. N-ERD currently lacks reliable clinical laboratory tests, yet early diagnosis and management are essential to prevent disease progression [2]. The pathogenesis of N-ERD has been linked to dysregulation of arachidonic acid (AA) metabolism, which affects levels of pro-inflammatory lipid mediators such as leukotrienes and prostaglandins [1, 3]. ASA alters AA metabolism by inhibiting cyclooxygenase (COX) enzymes and redirecting lipid synthesis towards pro-inflammatory leukotrienes [1]. Despite extensive research into eicosanoids in N-ERD, the full spectrum of lipid mediators involved remains incompletely understood. In this study, we investigated the effect of a low dose of ASA (25 mg) on plasma and urine lipid mediator concentrations in N-ERD patients compared with healthy controls, aiming to identify novel biomarkers and deepen understanding of disease mechanisms. This study included eight consecutively recruited N-ERD patients and seven age-matched healthy controls (25-62 years). All subjects were Finnish females, selected to minimise demographic variability. ...
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Allergology, Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- Department of Otorhinolaryngology, University of Eastern Finland, Joensuu and Kuopio, Finland.
- Department of Otorhinolaryngology-Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.
- Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
- Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland.
ORCID-Profile: Viljami E Salmi, Annina Lyly
Förderung
- Jalmari ja Rauha Ahokkaan Säätiö
- Suomen Allergologi- ja immunologiyhdistys
- Suomen Rinologiyhdistys - Consociatio Rhinologica Fennica
- Yrjö Jahnssonin Säätiö
- Väinö ja Laina Kiven Säätiö
- Paulon Säätiö
- Sigrid Juséliuksen Säätiö
- Orionin Tutkimussäätiö
Zitieren
APA
Salmi, V. E., Lyly, A., Neuvonen, M., Saarentaus, E., Niemi, M., & Toppila-Salmi, S. (2026). Systemic N‐Acylethanolamines and Other Lipid Mediators Are Associated With NSAID ‐Exacerbated Respiratory Disease. Clinical & Experimental Allergy, 56(1), 95-98. https://doi.org/10.1111/cea.70145
Vancouver
Salmi VE, Lyly A, Neuvonen M, Saarentaus E, Niemi M, Toppila-Salmi S. Systemic N‐Acylethanolamines and Other Lipid Mediators Are Associated With NSAID ‐Exacerbated Respiratory Disease. Clinical & Experimental Allergy. 2026;56(1):95-98. doi:10.1111/cea.70145
BibTeX
@article{Salmi2026,
author = {Salmi, Viljami E and Lyly, Annina and Neuvonen, Mikko and Saarentaus, Elmo and Niemi, Mikko and Toppila-Salmi, Sanna},
title = {Systemic N‐Acylethanolamines and Other Lipid Mediators Are Associated With NSAID ‐Exacerbated Respiratory Disease},
journal = {Clinical & Experimental Allergy},
year = {2026},
volume = {56},
number = {1},
pages = {95--98},
doi = {10.1111/cea.70145}
}
EUVIMED